A double-blind, controlled study of botulinum toxin A in chronic myofascial pain

Neurology

Volumn 67, Issue 2, 2006, Pages 241-245

  Qerama, E ^a,b   Fuglsang Frederiksen, A ^a   Kasch, H ^a   Bach, F W ^a   Jensen, T S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Building 10 ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; SODIUM CHLORIDE; ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ANTINOCICEPTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; ELECTRIC ACTIVITY; ELECTROMYOGRAM; ENDPLATE POTENTIAL; FEMALE; HUMAN; MALE; MECHANICAL STIMULATION; MOTION; MUSCLE; MUSCLE CONTRACTION; MYOFASCIAL PAIN; NECK PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; REST; SHOULDER; STANDARDIZATION; TREATMENT OUTCOME; TRIGGER POINT; VOLUNTARY MOVEMENT; CHRONIC DISEASE; MIDDLE AGED;

ANALGESICS; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOFASCIAL PAIN SYNDROMES; PAIN MEASUREMENT; PAIN THRESHOLD; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 33747065291     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000224731.06168.df     Document Type: Article

References (40)

1. Pearce LB, Borodic GE, Johnson EA, et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon 1995;33:217-227.
2. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Invest Drugs 2001;10:1531-1544.
3. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, et al. Long-term botulinum toxin treatment of cervical dystonia-EMG changes in injected and noninjected muscles. Clin Neurophysiol 1999;110:1650-1654.
4. Fuglsang-Frederiksen A, Ostergaard L, Sjo O, et al. Quantitative electromyographical changes in cervical dystonia after treatment with botulinum toxin. Electromyogr Clin Neurophysiol 1998;38:75-79.
5. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133.
6. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42.
7. Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003;61:940-944.
8. Blersch W, Schulte-Mattler WJ, Przywara S, et al. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002;205:59-63.
9. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001;94:255-260.
10. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23:1662-1666.
11. Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41:658-664.
12. Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000;40:300-305.
13. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 2002;99:465-473.
14. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004;109:110-114.
15. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol 2000;27:481-484.
16. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-450.
17. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-69.
18. Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001;56:1290-1293.
19. Travell D, Simons DG. Myofascial pain and dysfunction: the trigger point manual, upper half of the body. Baltimore, MD: Williams & Wilkins; 1999.
20. Graff-Radford SB. Myofascial pain: diagnosis and management. Curr Pain Headache Rep 2004;8:463-467.
21. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993;18:1803-1807.
22. Couppe C, Midttun A, Hilden J, et al. Spontaneous needle electromyographic activity in myofascial trigger points in the infraspinatus muscle. A blinded assessment. J Musculoskel Pain 2001;9:7-16.
23. Simons DG. Do endplate noise and spikes arise from normal motor endplates? Am J Phys Med Rehabil 2001;80:134-140.
24. Qerama E, Fuglsang-Frederiksen A, Kasch H, et al. Evoked pain in the motor endplate region of the brachial biceps muscle: An experimental study. Muscle Nerve 2004;29:393-400.
25. Bendtsen L, Jensen R, Olesen J. Qualitatively altered nociception in chronic myofascial pain. Pain 1996;65:259-264.
26. Buchthal F, Rosenfalck P. Spontaneous electrical activity of human muscle. Electroencephalogr Clin Neurophysiol 1966; 321-336.
27. Wiederholt WC. "End-plate noise" in electromyography. Neurology 1970;20:214-224.
28. Buchthal F. Spontaneous electrical activity: an overview. Muscle Nerve 1982;5:S52-S59.
29. Dumitru D, King JC, Stegeman DF. Endplate spike morphology: a clinical and simulation study. Arch Phys Med Rehabil 1998;79:634-640.
30. Fuglsang-Frederiksen A. The utility of interference pattern analysis. Muscle Nerve 2000;23:18-36.
31. Christensen H, Fuglsang-Frederiksen A. Power spectrum and turns analysis of EMG at different voluntary efforts in normal subjects. Electroencephalogr Clin Neurophysiol 1986;64:528-535.
32. Finsterer J. EMG-interference pattern analysis. J Electromyogr Kinesiol 2001;11:231-246.
33. Finsterer J, Fuglsang-Frederiksen A. Quantification of concentric-needle-induced insertional activity by turn/amplitude analysis. J Electromyogr Kinesiol 2003;13:191-196.
34. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
35. Simons DG, Hong CZ, Simons LS. Endplate potentials are common to midfiber myofascial trigger points. Am J Phys Med Rehabil 2002;81:212-222.
36. Simons D. Prevalence of spontaneous electrical activity at trigger spots and at control sites in rabbit skeletal muscle. J Musculoskel Pain 1995;3.
37. Kamanli A, Kaya A, Ardicoglu O, et al. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2004;25:604-611.
38. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskel Disord 2004;19:28.
39. Kohlmann T. Musculoskeletal pain in the population. Schmerz 2003;17:405-411.
40. Mense S. The pathogenesis of muscle pain. Curr Pain Headache Rep 2003;6:419-425.